Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JWATM214，an Armored GPC3-directed CAR-T ，in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma ：a Single-arm, Open-label，Dose-escalation Study

NCT05926726 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05926726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JWATM214，an Armored GPC3-directed CAR-T ，in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma ：a Single-arm, Open-label，Dose-escalation Study
Lead sponsor
RenJi Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 31, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma